TW528755B
(en)
|
1996-12-24 |
2003-04-21 |
Glaxo Group Ltd |
2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
|
YU44900A
(en)
|
1998-01-31 |
2003-01-31 |
Glaxo Group Limited |
2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
|
US6413974B1
(en)
|
1998-02-26 |
2002-07-02 |
Aventis Pharmaceuticals Inc. |
6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
|
US6479487B1
(en)
|
1998-02-26 |
2002-11-12 |
Aventis Pharmaceuticals Inc. |
6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
|
PT1056745E
(en)
*
|
1998-02-26 |
2004-09-30 |
Aventis Pharma Inc |
2-TRANS- (4-AMINOCYCLOHEXYL) AMINO PURINS DISSUBSTITUTED IN 6.9
|
ATE246701T1
(en)
|
1998-06-23 |
2003-08-15 |
Glaxo Group Ltd |
2-(PURIN-9-YL)-TETRAHYDROFURAN-3,4-DIOL DERIVATIVES
|
JP2002193967A
(en)
*
|
2000-07-10 |
2002-07-10 |
Sumika Fine Chemicals Co Ltd |
Production method of 2,6-dichloropurine
|
US6861524B2
(en)
|
2000-10-31 |
2005-03-01 |
Aventis Pharmaceuticals Inc. |
Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
|
AR044519A1
(en)
|
2003-05-02 |
2005-09-14 |
Novartis Ag |
DERIVATIVES OF PIRIDIN-TIAZOL AMINA AND PIRIMIDIN-TIAZOL AMINA
|
GB0401334D0
(en)
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
GB0411056D0
(en)
|
2004-05-18 |
2004-06-23 |
Novartis Ag |
Organic compounds
|
PE20060272A1
(en)
|
2004-05-24 |
2006-05-22 |
Glaxo Group Ltd |
(2R, 3R, 4S, 5R, 2'R, 3'R, 4'S, 5'S) -2.2 '- {TRANS-1,4-CYCLOHEXANODIYLBIS- [IMINO (2 - {[2- (1-METHYL- 1H-IMIDAZOL-4-IL) ETHYL] AMINO} -9H-PURIN-6,9-DIYL)]} BIS [5- (2-ETHYL-2H-TETRAZOLE-5-IL) TETRAHYDRO-3,4-FURANODIOL] AS AN A2A AGONIST
|
GB0424284D0
(en)
|
2004-11-02 |
2004-12-01 |
Novartis Ag |
Organic compounds
|
GB0426164D0
(en)
|
2004-11-29 |
2004-12-29 |
Novartis Ag |
Organic compounds
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
GB0514809D0
(en)
|
2005-07-19 |
2005-08-24 |
Glaxo Group Ltd |
Compounds
|
RU2421464C2
(en)
|
2005-10-21 |
2011-06-20 |
Новартис Аг |
Human il-13 antibodies and their therapeutic application
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
BRPI0717564A2
(en)
|
2006-09-29 |
2013-10-22 |
Novartis Ag |
PIRAZOLOPYRIMIDINES AS PI3K LIPID KINASE INHIBITORS
|
EP2089393A1
(en)
|
2006-10-30 |
2009-08-19 |
Novartis AG |
Heterocyclic compounds as antiinflammatory agents
|
ES2442930T3
(en)
|
2008-01-11 |
2014-02-14 |
Novartis Ag |
Pyrimidines as kinase inhibitors
|
ES2396023T3
(en)
|
2009-01-29 |
2013-02-18 |
Novartis Ag |
Substituted benzimidazoles for the treatment of astrocytomas
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
JP5781510B2
(en)
|
2009-08-12 |
2015-09-24 |
ノバルティス アーゲー |
Heterocyclic hydrazone compounds and their use for the treatment of cancer and inflammation
|
PT2467141T
(en)
|
2009-08-17 |
2019-02-06 |
Intellikine Llc |
Heterocyclic compounds and uses thereof
|
EP2467383A1
(en)
|
2009-08-20 |
2012-06-27 |
Novartis AG |
Heterocyclic oxime compounds
|
WO2012034095A1
(en)
|
2010-09-09 |
2012-03-15 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
UY33597A
(en)
|
2010-09-09 |
2012-04-30 |
Irm Llc |
COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF THE TRK
|
US20130324526A1
(en)
|
2011-02-10 |
2013-12-05 |
Novartis Ag |
[1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
WO2012116237A2
(en)
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
PE20140378A1
(en)
|
2011-02-25 |
2014-03-28 |
Irm Llc |
COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF TRK
|
ES2691650T3
(en)
|
2011-09-15 |
2018-11-28 |
Novartis Ag |
3- (quinolin-6-yl-thio) - [1,2,4] -triazolo- [4,3-a] -pyridines 6-substituted as inhibitors of tyrosine kinase c-Met
|
CN104363914A
(en)
|
2011-11-23 |
2015-02-18 |
因特利凯有限责任公司 |
Enhanced treatment regimens using mtor inhibitors
|
MX371119B
(en)
|
2012-04-03 |
2020-01-17 |
Novartis Ag |
Combination products with tyrosine kinase inhibitors and their use.
|
EP2968340A4
(en)
|
2013-03-15 |
2016-08-10 |
Intellikine Llc |
Combination of kinase inhibitors and uses thereof
|
WO2015084804A1
(en)
|
2013-12-03 |
2015-06-11 |
Novartis Ag |
Combination of mdm2 inhibitor and braf inhibitor and their use
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
EP3174869B1
(en)
|
2014-07-31 |
2020-08-19 |
Novartis AG |
Combination therapy of a met inhibitor and an egfr inhibitor
|
EP3749697A4
(en)
|
2018-02-05 |
2021-11-03 |
Bio-Rad Laboratories, Inc. |
Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand
|
TW202140550A
(en)
|
2020-01-29 |
2021-11-01 |
瑞士商諾華公司 |
Methods of treating an inflammatory or obstructive airway disease using anti-tslp antibody
|